Evaluating The effectiveness of Reducing Price Barriers to Pediatric Fever Care on Caregiver Decision-making and Illness Outcomes

How to cite

Dieci, Maria; Paramo, Carlos. 2026. "Evaluating The effectiveness of Reducing Price Barriers to Pediatric Fever Care on Caregiver Decision-making and Illness Outcomes." AEA RCT Registry. AEARCTR-0019380. https://doi.org/10.1257/rct.19380-1.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Maria Dieci* , Carlos Paramo

* Primary investigator

Registry ID
AEARCTR-0019380
DOI
https://doi.org/10.1257/rct.19380-1.0
First registered
Last updated
Status
In development
Trial dates
2026-09-01 – 2028-01-31
Countries
Private
Registry record
http://www.socialscienceregistry.org/trials/19380

Abstract

Background: Febrile illness is a leading cause of serious illness and death for millions of children across sub-
Saharan Africa, despite the availability of diagnostics and appropriate medications. Unfortunately, many fevers
are not treated appropriately due to financial barriers, incorrect or no diagnosis, and inappropriate use of
medications. Inappropriate treatment has uncertain health and economic costs to individuals as well as at a
population level. Objective: The primary objective of this trial is to determine the effectiveness and cost-
effectiveness of pharmacy-based discounts for appropriately dosed azithromycin compared with incentives for
facilitated referrals to a higher level health care facility in the management of malaria negative fevers in children
under five years in Uganda

Intervention

Control group: All study sites, including the control, have access to price subsidies for ORS, malaria RDTs, malaria ACTs, and over-the- counter painkillers. All study sites, including the control, will have access to referral information to nearby clinics.

Azithromycin discount group: Pharmacies assigned to this arm, in addition to having access to the subsidies and information described in the control group, will also have access to subsidized azithromycin for malaria negative children under 5.

Facilitated referral group: In addition to what is described for the control group, this arm will have access to subsidies for facilitated referrals to nearby clinics (incentives for patients and providers to complete referrals).

Experimental design

A sample of 200 eligible pharmacies in Uganda will be randomized into one of three study arms: (1) a control group, (2) a discounted azithromycin group, which offers subsidized prices for Azithromycin to eligible pediatric febrile cases who seek care in the pharmacy, (3) a facilitated referral group, which provides transport allowances facilitate referral visits for follow up care at nearby clinics to eligible pediatric febrile cases who seek care in the pharmacy

Design details

Randomization method
Stratified randomization done in office by lead investigators. Random seed will be set to equal the Makerere University IRB protocol number for the trial (202630).
Randomization unit
Cluster-level randomization at the pharmacy level.
Clusters
200 pharmacies
Observations
4800 pediatric febrile cases
Arms
80 pharmacies control, 60 pharmacies discounted azithromycin (30 heavy discount, 30 moderate discount), 60 pharmacies facilitated referral (30 high transport allowance, 30 moderate transport allowance)
Primary outcomes
Illness duration, defined as days to resolution of febrile illness in target child.
Secondary outcomes
Antibiotics uptake (AZ and otherwise), completed referrals, illness severity, indicators for appropriate and inappropriate clinical advice and treatment courses, and out of pocket spending.

Cited by

No citation data available for this registration yet.

Keywords